A New Patent Dance: The Biologics Price Competition and Innovation Act
|
|
- Tiffany Horton
- 6 years ago
- Views:
Transcription
1 A New Patent Dance: The Biologics Price Competition and Innovation Act J. Eric Thies David M. Conca Jeffrey A. Wolfson Jeffrey L. Kopacz Michael K. Kirschner
2 J. Eric Thies Assistant Counsel, Intellectual Property Group at Merck Rahway, NJ Chair, IPO Pharmaceutical Issues Committee 2
3 David M. Conca Partner, Litigation Department at Paul, Hastings, Janofsky & Walker, LLP New York, NY Chair of IPO Pharmaceutical Issues Subcommittee on Healthcare Legislation Moderator 3
4 Jeffrey A. Wolfson Partner at Haynes and Boone, LLP Washington, DC Vice-Chair of IPO Pharmaceutical Issues Subcommittee on Healthcare Legislation Panelist 4
5 Jeffrey L. Kopacz Senior Patent Counsel at Alnylam Pharmaceuticals Cambridge, MA Panelist 5
6 Michael K. Kirschner Hillis Clark Martin & Peterson, P.S. Seattle, WA Panelist 6
7 Presentation Outline Part 1: Overview of New Legislation Part 2: Hypothetical Patent Information Exchange Part 3: Resulting Litigation Part 4: FDA Regulatory Implementation 7
8 Part 1: Overview Title: Biologics Price Competition and Innovation Act of 2009 Effective date: March 23, 2010 Amends Section 351 of the Public Health Service Act to provide for abbreviated pathway for biosimilars based on regulatory data previously submitted for reference product 42 U.S.C. 262 (2010) 8
9 Part 1: Overview Data exclusivity for reference products, including pediatric exclusivity extension Regulatory pathway for biosimilars, including interchangeability incentives New patent litigation procedures with obligations on each side to disclose information 9
10 Part 1: Overview A follow on biologic can still be approved under 21 U.S.C. 355(b)(2) (505(b)(2)) if: The follow on biologic is in the same product class as the original biologic The original biologic was approved under section 505(b)(1) Not later than March 23, 2010 The follow on biologic application is submitted before March 23, U.S.C. 262 Note: PL (e)(1)-(e)(2) 10
11 Part 1: Overview (cont.) Exception: a follow on biologic application may not be submitted under 21 U.S.C. 355 if: Another biologic is approved under 42 U.S.C. 262 that could be a reference product for the follow on biologic application if submitted under that section 42 U.S.C. 262 Note: PL (e)(4) 11
12 Part 1: Overview (cont.) Phase Out: an approved application for a biologic under 21 U.S.C. 355 will be deemed a license for the biologic under 42 U.S.C. 262 on March 23, U.S.C. 262; PL (e)(4) 12
13 Deemed a License under such section 351 An approved application under Section 505 (21 U.S.C. 355) shall be deemed to be a license for the biological product under such section 351 on March 23, Exclusivity under 351 is for 12 years after the date on which the reference product was first licensed under subsection (a) PL (e)(4); 42 U.S.C. 262(k)(7)(A) 13
14 Part 2: Hypothetical Exchange Reference product sponsor Real Pharmaceutical Sciences, Inc. (RPS) files a biologics license application (BLA) under 351 for its drug Humorex, a biologic used to treat ipthealgia, a disease that produces uncontrollable, deadly laughter. RPS has obtained patents on the drug and processes of making it. RPS receives FDA approval for Humorex. 14
15 Part 2: What does that get RPS? Humorex is then entitled to 12 years of regulatory exclusivity Biosimilar applications cannot be filed less than 4 years after the date Humorex is approved 42 U.S.C. 262(k)(7)(A)-(B), (m)(3)-(4) RPS approval No Biosimilars Data Exclusivity Expires 4 years 12 years Discussion: What does regulatory exclusivity really mean? Compare Hatch-Waxman? Four year date? 15
16 Part 2: Pediatric Exclusivity? Pediatric exclusivity nets reference product sponsor an extra 6 months of regulatory exclusivity: Initial follow on biosimilar applications and their approval delayed 6 months, but Only if appropriate pediatric studies done and submitted and accepted under 505A at least 9 months before expiration of relevant period 42 U.S.C. 262(k)(7)(A)-(B), (m)(3)-(4) 16
17 Result of Pediatric Exclusivity 4 years 6 months 6 months 12 years Discussion: File for pediatrics late to extend twelve year term late rather than early? 17
18 Part 2: RPS can t get data exclusivity on A supplement to the original Humorex BLA; or A subsequent application (by RPS or a related entity) for Change (not structural) resulting in new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device, or strength; or Structural modification that does not result in change in safety, purity, or potency 42 U.S.C. 262(k)(7)(C) Discussion: Compare prior data necessary to get NCE. Is there guidance on threshold data required to show safety, purity, potency? 18
19 Part 2: Four Years Into Data Exclusivity 4 years after Humorex s approval, Biosimilar Aspirations, Ltd. (BA) files with the FDA an application for Funni, a biosimilar that claims Humorex as the reference biologic. BA also is called the subsection (k) applicant or sub(k) applicant. RPS approval BA can apply Data Exclusivity Expires 4 years 12 years 19
20 Part 2: FDA Guidance for BA FDA may issue guidance for approval of biosimilars, but it doesn t have to do so Guidance documents may state that FDA will not currently license a biosimilar for a certain product or class because science and experience currently does not allow it. But issuance or non-issuance of guidance shall not preclude FDA from reviewing or acting on an application FDA can later reverse or modify its position 42 U.S.C. 262(k)(8) Discussion: How/whether FDA guidance will affect followon biologic development. 20
21 Part 2: FDA Guidance for BA Product Class-Specific Guidance If issued, it must include criteria to determine both highly similar and interchangeable Public comment period 42 U.S.C. 262(k)(8)(D) Discussion: How/whether class-specific guidance will affect follow-on biologic development. 21
22 Part 2: What does BA have to show? For the FDA to approve Funni, BA has to prove that it is Biosimilar Optionally, BA can try to show that it is interchangeable Also, BA must show that the facility where Funni is manufactured, processed, packed, or held meets standards to ensure safety, purity, and potency 42 U.S.C. 262(k)(2)(A)(i), (k)(2)(b) Discussion: Investing/developing manufacturing facilities very early in biosimilar product s life cycle 22
23 Part 2: What is biosimilarity? 1. Highly similar to reference product notwithstanding minor differences in clinically inactive components; and 2. No clinically meaningful differences with regard to safety, purity, and potency 42 U.S.C. 262(i)(2) (as amended) Discussion: What showing will BA have to make for highly similar? 23
24 Part 2: Biosimilarity Studies I. Biosimilarity must be shown by: a) Analytical studies demonstrating that Funni is highly similar to Humorex notwithstanding minor differences in clinically active components; b) Animal studies (including assessment of toxicity); c) Clinical studies that demonstrate safety, purity, and potency in one or more conditions of use for which Humorex is licensed and intended to be used and for which licensure is sought But FDA can waive one or more biosimilarity studies 42 U.S.C. 262(k)(2)(A)(i)(I)-(II), (k)(2)(a)(ii) Discussion: What will FDA waive? Compare to Hatch-Waxman (bioequivalence studies) and European biosimilar pathway. 24
25 Part 2: What Else is Required for BA Licensure? II. Demonstration of the same mechanism or mechanisms of action, to the extent mechanisms of action are known to RPS III. Used for the same indications IV. Same route of administration, dosage form, and dosage strength as reference product; and V. Manufactured under FDA standards Discussion: Doctrine of Equivalents? 25
26 Part 2: Interchangeability BA must demonstrate that Funni is biosimilar to Humorex and Expected to produce the same clinical results; and If administered more than once to an individual, the risk of altering or switching is not greater than risk of using the reference product without alteration or switch 42 U.S.C. 262(k)(4) Discussion: Clinical studies necessary for switching? What are the risks? 26
27 Part 2: Interchangeability A determination of interchangeability would mean that Funni could be substituted for Humorex without the intervention of the health care provider that prescribed Humorex 42 U.S.C. 262(i)(3) (as amended) Discussion: How will this affect TE codes? What will be the market impact of biosimilar vs. interchangeable designation? 27
28 Part 2: Incentives to Prove Interchangeability, but If FDA determines that Funni is interchangeable with Humorex, BA gets data exclusivity against any other potential interchangeable biologics To the earlier of: 1 year after first commercial marketing of first interchangeable product; 18 months after a final court decision on all patents in suit in an action under this section against the first approved interchangeable product, or dismissal of an action under this section against first interchangeable product; 42 U.S.C. 262(k)(6) Discussion: BA only gets exclusivity as against other interchangeables. 28
29 Part 2: Incentives to Prove Interchangeability, but 42 months after approval of first interchangeable product if applicant has been sued under this section and litigation is still ongoing within the 42 month period; or 18 months after approval of first interchangeable product if applicant has not been sued under this section 42 U.S.C. 262(k)(6) Discussion: Impact on settling these cases? 29
30 Part 2: What else is in BA s application? Publicly-available information regarding the previous determination that reference product Humorex is safe, pure, and potent BA may include any other information to support the application, including publicly-available information about Humorex or another biological product However, BA s Funni application will not be evaluated for biosimilarity against more than one reference product 42 USC 262(k)(2)(iii); (k)(5) Discussion: What would you include if you were BA? 30
31 Part 2: After BA sends its application to FDA Once BA sends its biosimilar application to FDA with Humorex as its reference product, the FDA will notify it that the application was accepted for review. BA then has an obligation to notify RPS. 42 USC 262(l)(2) 31
32 Part 2: What Obligations Does BA have to RPS? Within 20 days after notification by the FDA, BA must provide RPS s counsel (under confidentiality provisions) A copy of its application for Funni Information about its manufacturing process BA may also provide: Any other information RPS requests and BA thinks appropriate to provide 42 USC 262(l)(2) Discussion: What would appropriate information be? Should BA include such information? 32
33 Part 2: Confidentiality Provisions for the Exchange of Information BA does not need to negotiate a protective order because confidentiality provisions are in the statute BA may not deny access to its biosimilar application (and other information exchanged between BA and RPS) to: RPS Outside counsel: one or more attorneys (if they do not engage formally or informally in relevant or related patent prosecution) RPS In-house counsel: one attorney with the same patent prosecution bar 42 U.S.C. 262(l)(1)(A)-(B) Discussion: Will parties need to negotiate the meaning of relevant patent prosecution for inside counsel? 33
34 Part 2: Confidentiality Provisions (cont.) BA may also not deny access to: A representative of a patent owner, where patent is exclusively licensed to RPS and right to sue has been retained, so long as owner agrees to be bound by the confidentiality provisions No disclosure to any other person without BA s consent But cannot be unreasonably withheld RPS and BA can negotiate a different protective order 42 U.S.C. 262(l)(1)(A)-(C) Discussion: Who else? Experts? Internal RPS employees? 34
35 Part 2: Exchange of Patent Information and Lists (The Dance) First Step: BA Provides Application to RPS Then during this exchange, RPS and BA each identify patents they think are relevant. BA provides application to RPS RPS provides patent list BA responds with reasoning RPS responds with reasoning Patent List Negotiation Day 1 Day 61 Day 121 Day 181? 35
36 Part 2: Second Step RPS Provides Its List to BA Within 60 days of receipt of information from BA, RPS must provide: List of all patents for which RPS believes a claim of patent infringement could reasonably be asserted Which of those patents it is prepared to license to BA 42 U.S.C. 262(l)(3)(A) Discussion: pre-suit investigations? 36
37 Part 2: Second Step RPS s Initial List to BA RPS: Humorex is covered by 6 patents which we believe will be infringed by Funni: We are willing to license the 005 patent. Discussion: With short deadlines, what should BA do to prepare for this exchange? 37
38 Part 2: Third Step BA Responds to RPS s Initial List BA must respond within 60 days: Factual and legal basis for belief each patent is invalid, unenforceable, or will not be infringed; or Will not begin commercial marketing until patent expires; and Response to each patent RPS will license What does the response need to be? BA can include its own list of patents on which it believes a claim of infringement could reasonably be asserted 42 U.S.C. 262(l)(3)(B) Discussion: What if there are several patents? What about 20? 38
39 Part 2: Third Step BA s Response to RPS s Initial List We will not infringe 001. The 002, 003, 004 and 006 are invalid or unenforceable. We do not need to license 005 because we also think it is invalid or unenforceable. These patents are not infringed, invalid, and/or unenforceable because Note that BA must provide a response to an offer to license 42 U.S.C. 262 (3)(B)(iii) 39
40 Part 2: Fourth Step RPS Responds to BA RPS must respond within 60 days Detailed statement describing factual and legal basis for belief that the patent will be infringed Response to statement concerning validity and enforceability 42 U.S.C. 262(l)(3)(C) Discussion: Response to validity and enforceability. 40
41 Part 2: Fourth Step RPS s Response to BA You will infringe patents They are all valid and enforceable for the following reasons RPS must provide its reasons for infringement, validity, and enforceability, showing its position to BA 41
42 Part 2: Fifth Step Patent List Negotiations RPS and BA must engage in good faith negotiations regarding which patents will be subject of the immediate infringement action 42 U.S.C. 262(l)(4)(A) Discussion: When should those negotiations begin? What do BA and RPS need to do to show good faith? 42
43 Part 2: Sixth Step Final Patent Lists What if RPS and BA fail to reach agreement on which patents to litigate within 15 days? They must then exchange final patent lists that will determine which patents will be litigated immediately 42 U.S.C. 262(l)(4)(B) 43
44 Part 2: Sixth Step Final Patent Lists BA notifies RPS of the number of patents that should be the subject of the infringement action Within 5 days parties simultaneously exchange lists of patents that should be the subject of the infringement action RPS cannot list more patents than the number proposed by BA (except if BA does not list any patent, then RPS can list one) 42 U.S.C. 262(l)(5) 44
45 Part 2: What Will RPS and BA Do in This Exchange? BA: We believe that 3 patents should be the subject of immediate litigation. RPS: We choose patents 002, 003, and 004. BA: We choose 002, 003, and 006. They still haven t come to agreement Discussion: Strategies for dealing with this? 45
46 Part 3: Litigation If the parties agree on a list RPS must commence action with respect to each patent on the list within 30 days of the agreement If the parties do not agree on a list RPS must commence action with respect to each patent on either list within 30 days of the exchange of the lists of patents during negotiations 42 U.S.C. 262(l)(6) 46
47 Part 3: RPS Must Sue on Four Patents Because RPS and BA didn t agree, RPS must commence litigation on patents 002, 003, 004 and 006 within 30 days of the exchange of final patent lists BA must notify FDA of the litigation If RPS and BA had agreed, only 3 patents would be litigated immediately Discussion: Is it more advantageous to agree or disagree? Is it okay to preview lists to ensure agreement/disagreement? 47
48 Part 3: Bringing an Action for Infringement: Limitations Bringing action after the 30 days has expired or bringing action then dismissing it without prejudice Sole remedy in any subsequent infringement action of that patent will be reasonable royalty Failure to disclose relevant patent Action for patent infringement under this section can never be brought No provision prohibiting settlement 35 U.S.C. 271(e)(6) Discussion: Does this section mean 271(e) or 271? 48
49 Part 3: Notice of Commercial Marketing and Preliminary Injunction Notice of intent to market BA must provide at least 180 days notice of intention to market, regardless of existence of patents Preliminary injunction RPS can seek a preliminary injunction after receiving BA s notice 42 U.S.C. 262(l)(8) To prevent marketing until court decides infringement, validity, and enforceability Discussion: Will there be substantial PI practice? 49
50 Part 3: Preliminary Injunction (Cont.) Eligible patents Patents in the original list of either of the parties, or in a newly issued patents list, but that are not included in the final lists (after negotiations) Parties must reasonably cooperate to expedite further discovery as needed for preliminary injunction 42 U.S.C. 262(l)(8) 50
51 Part 4: FDA Implementation FDA is given substantial discretion under the statute Unclear how FDA will implement the statute If FDA issues guidance on a case-by-case basis, an approval pathway will be difficult to predict for other biosimilar applicants Unclear what studies FDA will require, which could affect decisions by biosimilar applicants of which products to develop Discussion: What do you guys think? 51
52 Part 4: Recent FDA Actions The agency is in the early stages of deciding on an approval pathway A working group comprised of officials from CDER, CBER, and the Office of the Chief Counsel has been established by FDA to implement the statute Leah Christi has been tapped as the Office of New Drugs Associate Director of Biosimilars What else? Washington Drug Letter, Vol. 42 No. 25, Biosimilar Developers Told to Wait as FDA Crafts Regulatory Guidance, June 21, 2010; The Pink Sheet Daily, FDA Creates Biosimilars Overseer in Drug Office; Internal Panel to Advice Application Reviewers, May 20,
Patient Protection and Affordable Care Act (H.R. 3590) Approval Pathway for Biosimilar Biological Products
Approval Pathway for Biosimilar Biological Products On December 24, 2009, the U.S. Senate passed the, its version of comprehensive healthcare reform legislation. On March 21, 2010, the U.S. House of Representatives
More informationPharmaceutical Intellectual Property Summit Biosimilars Panel. Janis Fraser, moderator October 28, 2010 Princeton, NJ
Pharmaceutical Intellectual Property Summit Biosimilars Panel Janis Fraser, moderator October 28, 2010 Princeton, NJ Pharmaceutical Intellectual Property Summit Biosimilars Panel Terry G. Mahn October
More informationAbout a year ago, President
FOCUS ON... The regs The New US Biosimilar Legislation, One Year Later by Jacqueline Wright Bonilla and Nathan Beaver About a year ago, President Obama signed into law the highly publicized health care
More informationKey Regulatory Issues in Biosimilars
Key Regulatory Issues in Biosimilars May 4, 2017 John Manthei, Esq. Moderator Latham & Watkins LLP Latham & Watkins operates worldwide as a limited liability partnership organized under the laws of the
More informationCopyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited.
Statutory Framework for Biologics Drugs Investigational Use Application IND Pre-Market Approval Applications 505(b)(1) NDA 505(b)(2) NDA 505(j) ANDA Over-the-Counter (OTC) Non- Rx Drugs Monograph Biologics
More informationBrief. IP Strategies in the Emerging Biosimilar Market. U.S. Patent Strategies in the Biosimilars Space. Biosimilar Litigation Landscape
Brief IP Strategies in the Emerging Biosimilar Market U.S. Patent Strategies in the Biosimilars Space Biosimilar Litigation Landscape Decision Points and Strategies for the Patent Dance U.S. Patent Strategies
More informationA New Pathway for Follow-on Biologics. Steven A. Nash 1 Rebecca Workman 2 Connolly Bove Lodge & Hutz LLP 3
Steven A. Nash 1 Rebecca Workman 2 Connolly Bove Lodge & Hutz LLP 3 I. Introduction The recent passage of the Patient Protection and Affordable Care Act establishes an abbreviated pathway by which the
More informationOverview and Life Cycle Planning for Biosimilars
September 23, 2011 The Biosimilars i il Competition and Innovation Act: Overview and Life Cycle Planning for Biosimilars Stephen Paul Mahinka Chair, Life Sciences & Healthcare Interdisciplinary Group smahinka@morganlewis.com
More informationPatent Challenges Post-MMA Third Annual FDA Regulatory and Compliance Symposium
Third Annual FDA Regulatory and Compliance Symposium Presented by Richard J. Berman, Partner Arent Fox LLP Washington, DC August 23, 2007 Topics To Be Discussed Hatch-Waxman Summary Pre-MMA Law On Generic
More informationI. FDA s Proposed Revocation of Unexpired Regulatory Exclusivity Cannot Stand
May 13, 2016 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Draft Guidance for Industry: Implementation of the Deemed To Be a
More informationHigh Court Interprets The Biosimilars Statute What Now?
Portfolio Media. Inc. 111 West 19 th Street, 5th Floor New York, NY 10011 www.law360.com Phone: +1 646 783 7100 Fax: +1 646 783 7161 customerservice@law360.com High Court Interprets The Biosimilars Statute
More informationEffects Of Biosimilars Legislation On Patent Litigation
Portfolio Media, Inc. 648 Broadway, Suite 200 New York, NY 10012 www.law360.com Phone: +1 212 537 6331 Fax: +1 212 537 6371 customerservice@portfoliomedia.com Effects Of Biosimilars Legislation On Patent
More informationPediatric Exclusivity and Drug Development Requirements in the Overall Pediatric Population. Prepared by Beckloff Associates, Inc.
and Drug Development Requirements in the Overall Pediatric Population 1 INTRODUCTION AND OVERVIEW Prepared by Beckloff Associates, Inc. Although children suffer from many of the same diseases as adults
More informationI N S I D E T H E M I N D S
I N S I D E T H E M I N D S Recent Developments in Food and Drug Law Leading Lawyers on Dealing with Increased Enforcement, Keeping Up-To-Date with FDA Requirements, and Developing Compliance Practices
More informationFollow-On Biologics: Intellectual Property Issues
Follow-On Biologics: Intellectual Property Issues John R. Thomas Visiting Scholar August 28, 2015 Congressional Research Service 7-5700 www.crs.gov R44173 Summary The term biologics refers to a category
More informationModel Employment Contract
Model Employment Contract Adapt this Model Employment Contract for use at your own workplace. MODEL EMPLOYMENT CONTRACT HR managers in any part of the country can adapt this Model Employment Contract for
More informationDATA SHARING AGREEMENT
DATA SHARING AGREEMENT Effective Date: This Data Sharing Agreement ( Agreement ) is effective as of the Effective Date between EMD Serono, One Technology Place, Rockland, MA 02370 and Name ( Institution
More informationNonproprietary Naming of Biological Products
Nonproprietary Naming of Biological Products Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document
More informationChin Koerner Executive Director US Regulatory and Development Policy
Chin Koerner Executive Director US Regulatory and Development Policy Novartis Pharmaceuticals Corporation 1700 Rockville Pike Suite 510 Rockville, MD 20852 Tel 301.468.5607 Fax 301.468.5614 Email: Chin.Koerner@novartis.com
More informationEnergy Auction for the CPV Sentinel Generating Facility
Energy Auction for the CPV Sentinel Generating Facility Energy Auction Instructions and Terms and Conditions of Participation Updated June 11, 2013 A. GENERAL A.1. Company ( SCE ) seeks to sell, by this
More informationGuidance for Industry New Chemical Entity Exclusivity Determinations for Certain Fixed-Combination Drug Products
Guidance for Industry New Chemical Entity Exclusivity Determinations for Certain Fixed-Combination Drug Products DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments
More informationSIIA S CORPORATE ANTI-PIRACY REWARD PROGRAM
SIIA S CORPORATE ANTI-PIRACY REWARD PROGRAM The Software & Information Industry Association (SIIA) offers rewards of up to $1,000,000 to individuals who report verifiable corporate end-user piracy to SIIA
More informationMomenta Pharmaceuticals Reports First Quarter 2017 Financial Results
May 2, 2017 Momenta Pharmaceuticals Reports First Quarter 2017 Financial Results --Company reports Glatopa 20 mg product revenues of $23 million, a 58% increase over the same period in 2016-- --Ended the
More informationThe Michigan Freedom of Information Act and Its Impact on Financial Administrators at Michigan State University
The Michigan Freedom of Information Act and Its Impact on Financial Administrators at Michigan State University Ellen Armentrout Assistant General Counsel and FOIA Officer Michigan State University Office
More informationIN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE ) ) ) ) ) ) ) ) ) ) ) ) COMPLAINT INTRODUCTION
IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE ABBVIE INC. and ABBVIE BIOTECHNOLOGY LTD. Plaintiffs, v. AMGEN INC. and AMGEN MANUFACTURING LTD. Defendants. ) ) ) ) ) ) ) ) ) ) ) ) Civil
More informationACC February 2015 Quick Hit. FDA Hot Topics. David L. Rosen, B.S. Pharm., J.D. Foley & Lardner LLP (202)
1 ACC February 2015 Quick Hit FDA Hot Topics David L. Rosen, B.S. Pharm., J.D. Foley & Lardner LLP (202) 672-5430 drosen@foley.com 2013 Foley Foley && Lardner LLP LLP Attorney Advertising Prior Prior results
More informationBiosimilars: A Year in Review
January 18, 2018 Webinar Series: s s: A Year in Review John Adkisson Principal Twin Cities Tasha Francis Associate Twin Cities Jenny Shmuel Associate Boston Overview s Series Introduction to the area of
More informationGuidance for Industry
Reprinted from FDA s website by Guidance for Industry Scientific Considerations in Demonstrating Biosimilarity to a Reference Product DRAFT GUIDANCE This guidance document is being distributed for comment
More informationLEVERAGING OUR BIOLOGICS EXPERTISE IN BIOSIMILARS SCOTT FORAKER VICE PRESIDENT AND GENERAL MANAGER, BIOSIMILARS
LEVERAGING OUR BIOLOGICS EXPERTISE IN BIOSIMILARS SCOTT FORAKER VICE PRESIDENT AND GENERAL MANAGER, BIOSIMILARS SAFE HARBOR STATEMENT This presentation contains forward-looking statements that are based
More informationAmerican Academy of Orthopaedic Surgeons 2010 Annual Meeting
American Academy of Orthopaedic Surgeons 2010 Annual Meeting Off-Label Device Use: When Clinical Need Outpaces Regulatory Approval The Legal Parameters of Off-Label Use March 10, 2010 Kathleen McDermott
More informationImportant Facts. Health Care Professionals Should Know About Biosimilars
Important Facts Health Care Professionals Should Know About Biosimilars Biosimilars: Defining Characteristics Biosimilars are highly similar versions of reference biologics, with no clinically meaningful
More informationGeneral Terms of Jobrapido
General Terms of Jobrapido These General Terms (the "General Terms") will apply to the Client unless they are bypassed by specific terms contained in the Purchase Order; they will apply in general and
More informationMunicipal Cable Franchise Transfer Toolkit
Municipal Cable Franchise Transfer Toolkit By Gail Karish and Joseph Van Eaton A cable operator generally cannot transfer control of its business or transfer its cable franchise without the prior approval
More informationHow the Frank R. Lautenberg Chemical Safety for the 21st Century Act 1 amends the Toxic Substances Control Act of 1976 (TSCA) and
How the Frank R. Lautenberg Chemical Safety for the 21st Century Act 1 amends the Toxic Substances Control Act of 1976 (TSCA) and Reconciling and other changes made since House and Senate bill passage
More informationPHARMACEUTICAL ANTITRUST: Delayed Generic Entry Cases. December 7, 2011 Linda Nussbaum John Radice
PHARMACEUTICAL ANTITRUST: Delayed Generic Entry Cases December 7, 2011 Linda Nussbaum John Radice What is Pharma Antitrust? General antitrust principles applied to the pharmaceutical industry, generally
More informationFDA Public Hearing: Approval Pathway for Biosimilar. Products. November 2-3, 2010
FDA Public Hearing: Approval Pathway for Biosimilar and Interchangeable Biological Products November 2-3, 2010 1 The Biotechnology Industry Organization Over 1,100 members, including biotechnology companies,
More informationUPMC POLICY AND PROCEDURE MANUAL. Links to policies referenced within this policy can be found in Section V.
UPMC POLICY AND PROCEDURE MANUAL POLICY: INDEX TITLE: HS-EC1800 Ethics & Compliance SUBJECT: Corporate Ethics & Compliance Program DATE: April 1, 2016 I. STATEMENT OF PURPOSE It is the policy of UPMC to
More informationThe Construction Industry Labour Relations Act, 1992
1 CONSTRUCTION INDUSTRY LABOUR RELATIONS, 1992 c. C-29.11 The Construction Industry Labour Relations Act, 1992 Repealed by Chapter S-15.1 of the Statutes of Saskatchewan, 2013 (effective April 29, 2014)
More informationTracy U. Palovich, PhD Colleen M. Schaller. Howson & Howson LLP Blue Bell, Pennsylvania
Safe Harbor Exemption under 271(e)(1): What's not included after Momenta Pharmaceuticals, Inc. v. Amphastar Pharmaceuticals, 686 F.3d 1348, 103 USPQ2d 1800 (Fed. Cir 2012) Tracy U. Palovich, PhD Colleen
More informationNEW YORK STATE BAR ASSOCIATION FOOD, DRUG AND COSMETIC LAW SECTION AND HEALTH LAW SECTION COMMITTEE ON MEDICAL RESEARCH AND BIOTECHNOLOGY
NEW YORK STATE BAR ASSOCIATION FOOD, DRUG AND COSMETIC LAW SECTION AND HEALTH LAW SECTION COMMITTEE ON MEDICAL RESEARCH AND BIOTECHNOLOGY MEMORANDUM IN SUPPORT OF AN AMENDMENT TO NEW YORK S PHARMACY LAW
More informationUnder this license, you are approved to manufacture aflibercept drug substance intermediate, drug substance, and formulated bulk at
DEPARTMENT OF HEALTH AND HUMAN SERVICES Silver Spring MD 20993 Our STN: BL 125387/0 BLA APPROVAL November 18, 2011 Regeneron Pharmaceuticals, Inc. Attention: Laura Pologe, Ph.D. Associate Director, Regulatory
More informationNOTICE: THIS IS A LEGALLY BINDING CONTRACT Between Wellcome Trust Sanger Institute and the Recipient institution
NOTICE: THIS IS A LEGALLY BINDING CONTRACT Between Wellcome Trust Sanger Institute and the Recipient institution It is essential that the person signing this contract on behalf of the Recipient institution
More informationIN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE ) ) ) ) ) ) ) ) ) ) C.A. No. COMPLAINT
Case 1:99-mc-09999 Document 732 Filed 12/15/11 Page 1 of 10 PageID #: 67711 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE PFIZER INC., WYETH LLC. and WYETH PHARMACEUTICALS INC., v. SANDOZ
More informationIntellectual Property Guide for Host Institutions
Intellectual Property Guide for Host Institutions Office of the General Counsel Last Updated: July 2017 Introduction... 1 Disclosure and Assignment of Inventions... 1 Reporting Invention Disclosures...
More informationBILL NO. 23. (as passed, with amendments) 3rd Session, 61st General Assembly Nova Scotia 60 Elizabeth II, Government Bill
BILL NO. 23 (as passed, with amendments) 3rd Session, 61st General Assembly Nova Scotia 60 Elizabeth II, 2011 Government Bill Public Procurement Act CHAPTER 12 OF THE ACTS OF 2011 The Honourable Percy
More information2017 Renewable Energy Sale - Request for Offers Solicitation Protocol
2017 Renewable Energy Sale - Request for Offers Solicitation Protocol Issuance Date: Week of January 23, 2017 i Table of Contents I. OVERVIEW... 1 A. OVERVIEW... 1 B. RENEWABLE ENERGY SALE RFO COMMUNICATION...
More informationLouisiana Society for Human Resource Management
Louisiana Society for Human Resource Management 2017 Regular Session Bills of Interest The following are summaries of bills pending before the Louisiana Legislature during the 2017 Regular Session, and
More informationInvestigator-Initiated INDs
Investigator-Initiated INDs Marjorie Small, RN, CCRC Office of Clinical Research 23 May 2011 PPHS/IRB Research Grand Rounds Outline of Presentation I. What is an IND? II. Code of Federal Regulations III.
More informationREGULATORY ISSUES: HOW TO APPLY FOR AN IND. Penny Jester and Maaike Everts
REGULATORY ISSUES: HOW TO APPLY FOR AN IND Penny Jester and Maaike Everts Outline 2 What is the purpose of an IND? What types of INDs are there? When do you need one? How do you apply for one? How do you
More informationCase 2:18-cv Document 1 Filed 03/08/18 Page 1 of 65 PageID: 1
Case 2:18-cv-03347 Document 1 Filed 03/08/18 Page 1 of 65 PageID: 1 Liza M. Walsh Tricia B. O Reilly Katelyn O Reilly William T. Walsh, Jr. WALSH PIZZI O REILLY FALANGA LLP One Riverfront Plaza 1037 Raymond
More informationIF YOU DO NOT AGREE TO THESE TERMS, DO NOT DOWNLOAD, INSTALL OR USE BSS.
Bitvise SSH Server End User License Agreement Bitvise Limited, a Texas corporation with its principal office at 4105 Lombardy Court, Colleyville, Texas 76034, USA, ("Bitvise"), develops a Windows SSH server
More informationGENERAL ASSEMBLY OF NORTH CAROLINA SESSION 2017 H 1 HOUSE BILL 366. Short Title: Retail Workers' Bill of Rights. (Public)
GENERAL ASSEMBLY OF NORTH CAROLINA SESSION 0 H 1 HOUSE BILL Short Title: Retail Workers' Bill of Rights. (Public) Sponsors: Referred to: Representatives Brockman, Fisher, Harrison, and Holley (Primary
More informationDeveloping an Environmental Compliance Plan
Developing an Environmental Compliance Plan 1 Purpose: Complete and continuous environmental compliance in all areas can be a difficult and expensive challenge. To achieve and then maintain a high level
More informationWhy Primary Patents Covering Biologics Should Be Unforceable against Generic Applicants under the Biologics Price Competition and Innovation Act
Annals of Health Law Volume 21 Issue 1 Special Edition 2012 Article 20 2012 Why Primary Patents Covering Biologics Should Be Unforceable against Generic Applicants under the Biologics Price Competition
More informationHong Kong Exchange Publishes Draft Rules for Biotech Listings, Requests Comments
WHITE PAPER March 2018 Hong Kong Exchange Publishes Draft Rules for Biotech Listings, Requests Comments The Hong Kong Stock Exchange recently published a Consultation Paper on a Listing Regime for Companies
More informationA critical review of the current landscape Presentations
CLINICAL INNOVATION: Fair & Effective Incentives for New Uses of Established Drugs A critical review of the current landscape Presentations Presenters: Christoph de Coster Taylor Wessing LLP Elaine Herrmann
More informationCommittee Opinion May 6, 2008 CITY ATTORNEY PROVIDES LEGAL SERVICES TO MULTIPLE CONSTITUENTS WITHIN AN ORGANIZATION.
LEGAL ETHICS OPINION 1836 CONFLICTS OF INTEREST INVOLVED WHEN CITY ATTORNEY PROVIDES LEGAL SERVICES TO MULTIPLE CONSTITUENTS WITHIN AN ORGANIZATION. You have presented hypothetical situations in which
More informationINFRASTRUCTURE ONTARIO VENDOR PERFORMANCE PROGRAM
INFRASTRUCTURE ONTARIO VENDOR PERFORMANCE PROGRAM TABLE OF CONTENTS Preamble... 1 1. Definitions... 1 2. Purpose... 2 3. Evaluation of Vendor Performance... 3 3.1 Vendor Performance Scorecard... 3 3.2
More informationCONSIGNMENT AGREEMENT for ARTWORK. Whereas, Consignor wishes to display Artwork for sale at the Visitor Center or City Hall,
PAAC/City CONSIGNMENT AGREEMENT for ARTWORK This Consignment Agreement (the Agreement ) is made this date: * by and between * (the Consignor ), The City of Twentynine Palms (the City ), to provide the
More informationCFPB Investigations In Focus: Navigating CIDs
Portfolio Media. Inc. 860 Broadway, 6th Floor New York, NY 10003 www.law360.com Phone: +1 646 783 7100 Fax: +1 646 783 7161 customerservice@law360.com CFPB Investigations In Focus: Navigating CIDs Law360,
More informationActing Deputy Commissioner for Operations, U.S. Food and Drug Administration
Available on FDA website at: http://www.fda.gov/newsevents/testimony/ucm113266.htm Pediatric Clinical Trials for Anti-depressant Drug Products Statement of Janet Woodcock, M.D. Acting Deputy Commissioner
More informationROSNEFT OIL COMPANY'S REGULATION ON
APPROVED by Rosneft Order 703 dated "01" December 2016 Put into effect on "01" December 2016 ROSNEFT OIL COMPANY'S REGULATION ON PROVISION OF INFORMATION TO ROSNEFT SHAREHOLDERS P3-01.05 R-0018 REVISION
More informationPublic Procurement Act
Public Procurement Act CHAPTER 12 OF THE ACTS OF 2011 as amended by 2014, c. 34, ss. 35-38 2016 Her Majesty the Queen in right of the Province of Nova Scotia Published by Authority of the Speaker of the
More informationHow To Respond To CFPB Civil Investigative Demands
Portfolio Media. Inc. 860 Broadway, 6th Floor New York, NY 10003 www.law360.com Phone: +1 646 783 7100 Fax: +1 646 783 7161 customerservice@law360.com How To Respond To CFPB Civil Investigative Demands
More informationADVERTISING AGREEMENT
ADVERTISING AGREEMENT Company Name: Address: Postcode: Telephone: PACKAGE DETAILS Please select pricing option: 5 plays for 50 Campaign start date: SPEYSOUND RADIO LIMITED Suite 5, Aviemore Shopping Centre
More informationTo receive the $1 million prize, the successful candidate must be the first to do both of the following:
In Vitro Meat Production Contest Rules Summary People for the Ethical Treatment of Animals (PETA) aims with this contest to encourage the development and offering for sale of in vitro chicken meat in commercially
More informationEvaluate the Current Biosimilar Landscape and Strategies to Secure Access. Jim Van Lieshout August 16, 2017
Evaluate the Current Biosimilar Landscape and Strategies to Secure Access Jim Van Lieshout August 16, 2017 1 Disclosure Statement James R. Van Lieshout, Vice President, Trade and Industry Relations Apobiologix,
More informationSTATE OF RHODE ISLAND OFFICE OF THE GENERAL TREASURER
STATE OF RHODE ISLAND OFFICE OF THE GENERAL TREASURER REQUEST FOR QUALIFICATIONS To Serve as Legal Counsel to the State of Rhode Island Public Finance Management Board The Office of the General Treasurer
More informationHouse Bill 4086 Ordered by the House February 21 Including House Amendments dated February 21
th OREGON LEGISLATIVE ASSEMBLY--0 Regular Session A-Engrossed House Bill 0 Ordered by the House February Including House Amendments dated February Introduced and printed pursuant to House Rule.00. Presession
More informationPOLICY AND PROCEDURES. Office of Pharmaceutical Quality. Table of Contents
POLICY AND PROCEDURES Office of Pharmaceutical Quality NDA Classification Codes Table of Contents PURPOSE...1 BACKGROUND...1 POLICY...1 NDA Classification Codes...2 RESPONSIBILITIES...7 REFERENCES...9
More informationCopyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited.
Copyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited. Special Review Designations & Approval Pathways Special Designations
More informationDrop That Thumb Drive, and Get Back Here! Using Non-Competes and the Law of Trade Secrets to Protect and Maintain Your Competitive Advantage
Drop That Thumb Drive, and Get Back Here! Using Non-Competes and the Law of Trade Secrets to Protect and Maintain Your Competitive Advantage 33 rd Annual Labor & Employment Conference Paul A. Wilhelm Brian
More informationTitle II Licensure of Wholesale Distributors and 3PL s:
Title II Licensure of Wholesale Distributors and 3PL s: Where does FDA stand, where do states stand, what about VAWD, and what can you do about it? Elizabeth A. Gallenagh, Senior Vice President, Government
More informationAdditional Terms & Conditions for Social Network Influencers
Additional Terms & Conditions for Social Network Influencers This document contains additional Terms & Conditions ( T&C ) designed for mobile advertising through social networks, a market place into which
More informationInvited Researcher : VivianeYumy Mitsuuchi Kunisawa (**) Introduction
13 The Patentability and Scope of Protection of Pharmaceutical Inventions Claiming Second Medical Use the Japanese and European Approaches as Possible Paradigms for a Developing Country like Brazil (*)
More informationDisciplinary Actions, Suspension and Dismissal
Section 7, Page 1 Contents: Policy Covered Employees Definitions Just Cause for Disciplinary Action General Provisions Unsatisfactory Job Performance Grossly Inefficient Job Perform/Unacceptable Personal
More informationRegulatory Considerations and Trends Europe and the U.S.
Regulatory Considerations and Trends Europe and the U.S. Professor Kjell Strandberg MD PhD Chairman NDA Advisory Board, NDA Regulatory Science Ltd UK Former CPMP Member and Director General Medical Products
More informationANDA ANDA APPROVAL
DEPARTMENT OF HEALTH & HUMAN SERVICES ANDA 206726 Food and Drug Administration Silver Spring, MD 20993 ANDA APPROVAL Mylan Pharmaceuticals, Inc. 781 Chestnut Ridge Road P.O. Box 4310 Morgantown, WV 26504
More informationUNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS
Amgen Inc. v. F. Hoffmann-LaRoche LTD et al Doc. 976 Case 1:05-cv-12237-WGY Document 976 Filed 09/03/2007 Page 1 of 5 UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS AMGEN INC., Plaintiff, v. CIVIL
More informationEmployee termination decisions and contract non-renewal decisions are not subject to the informal resolution process.
MARATHON CITY SCHOOL DISTRICT 527 EMPLOYEE GRIEVANCE POLICY AND PROCEDURE 1 Informal Resolution: An employee 2 with a complaint related to employee discipline (except employee termination) or workplace
More informationEmployee Records I A S B. Illinois Personnel Records Review Act. Understanding requirements of the
I A S B Employee Records Understanding requirements of the Illinois Personnel Records Review Act by Terrence M. Barnicle Attorney with Klein, Thorpe and Jenkins, Ltd. Chicago 2921 Baker Drive One Imperial
More informationHuman Resources Directorate
Name of Policy Employee Records Privacy Policy Description of Policy New Policy Revision Description of Revision Human Resources Directorate Policy and Revision Number Original Effective Date Review Due
More informationPartnering with the NIH: Technology Transfer. Why partner?
Partnering with the NIH: Technology Transfer Jennifer Wong, M.S. Technology Development Coordinator National Institute of Mental Health Why partner? Enhance company s portfolio De-risks developing a technology
More informationWebinar Series: Biosimilars
May 23, 2017 Webinar Series: Biosimilars Recent and Upcoming BPCIA Guidance from the Federal Circuit and the Supreme Court John Adkisson Principal Twin Cities Tasha Francis Associate Twin Cities Jenny
More informationPrince Edward Island
ACCESSING GOVERNMENT INFORMATION IN Prince Edward Island RESOURCES Freedom of Information and Protection of Privacy Act (FOIPP) http://www.gov.pe.ca/law/statutes/pdf/f-15_01.pdf Prince Edward Island Freedom
More informationJames Cook University. Internal Audit Protocol
James Cook University Internal Audit Protocol Table of Contents A. Introduction 2 B. Management Consultation during the Annual Internal Audit Planning Process 2 C. Support Provided to QAO/External Auditor
More informationRe: Docket No. FDA-2014-D-1461: Rare Pediatric Disease Priority Review Vouchers
February 13, 2015 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Docket No. FDA-2014-D-1461: Rare Pediatric Disease Priority Review
More informationand B. R. Skelton, Arbitrator REGULAR ARBITRATION PANEL In the Matter of the Arbitration GRIEVANT : Class Action CASE NO : S7N-3S-C & 88050
REGULAR ARBITRATION PANEL In the Matter of the Arbitration between UNITED STATES POSTAL SERVICE GRIEVANT : Class Action CASE NO : S7N-3S-C 88049 & 88050 GTS NO : 12115 & 12116 and NATIONAL ASSOCIATION
More informationThe Role of Comparative Analyses for Evaluation of Generic Drug-Device Combinations in an ANDA
The Role of Comparative Analyses for Evaluation of Generic Drug-Device Combinations in an ANDA K. Witzmann, MD Inhalation and Drug-Device Combination Products Team Office of Research and Standards, Office
More informationAppropriate Role of Contractors Supporting the Government Working Group: Presentation of Recommendations 12/16/2005
PRELIMINARY WORKING GROUP DRAFT For Discussion Purposes Only Not Reviewed or Approved by the Acquisition Advisory Panel Appropriate Role of Contractors Supporting the Government Working Group: Presentation
More informationDispute Resolution for postal disputes
Dispute Resolution for postal disputes Supplement to Ofcom s guidelines for the handling of regulatory disputes On 1 October 2011, the Postal Services Act 2011 (the 2011 Act ) came into force, giving Ofcom
More informationDetermining Whether a Proposal is Subject to the National Environmental Policy Act (NEPA) Section 102 Updated March
Determining Whether a Proposal is Subject to the National Environmental Policy Act (NEPA) Section 102 Updated March 2005 1 This paper presents some key thresholds to consider when determining whether a
More informationNonproprietary Naming of Biological Products; Draft Guidance for Industry; Docket No. FDA 2013 D 1543 October 27, 2015
Electronic Submission via http://www.regulations.gov Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, Maryland 20852 Re: Nonproprietary Naming
More informationUTAH VALLEY UNIVERSITY Policies and Procedures
Page 1 of 8 POLICY TITLE Section Subsection Responsible Office Conflict of Interest Governance, Organization, and General Information Governance and Organization Office of the Vice President of Finance
More informationProfessional Practice 544
February 22, 2016 February 29, 2016 Professional Practice 544 AIA-B101 Owner - Architect Agreement Michael J. Hanahan Schiff Hardin LLP 233 S. Wacker, Ste. 6600 Chicago, IL 60606 312-258-5701 mhanahan@schiffhardin.com
More informationCLICKBANK ADVERTISING TERMS AND CONDITIONS
Last Updated Date: January 24, 2013 CLICKBANK ADVERTISING TERMS AND CONDITIONS These ClickBank Advertising Terms and Conditions ("Terms") shall be deemed incorporated by reference into any insertion order
More information2018 AASHE Bulletin Advertising Agreement
2018 AASHE Bulletin Advertising Agreement This AASHE Bulletin Advertising Agreement (the Agreement ) is made by and between the Association for the Advancement of Sustainability in Higher Education ( AASHE
More informationPost-approval Change Management Protocols - Current Status and Next Steps on the Way towards a Global Tool
Post-approval Change Management Protocols - Current Status and Next Steps on the Way towards a Global Tool Dr. Markus Goese Lead EU CMC Regulatory Policy F. Hoffmann-La Roche Ltd, Basel - Switzerland Presentation
More informationEEOC Pay Equity Enforcement
EEOC Pay Equity Enforcement January 24, 2013 Paul C. Evans Blair J. Robinson www.morganlewis.com Agenda EEOC Strategic Enforcement Plan Enforcing equal pay laws EEOC Investigations and Enforcement Investigative
More informationRailroad Commission of Texas Mentor Protégé Program
Railroad Commission of Texas Mentor Protégé Program December 3, 2002 1 1.0 Description The Railroad Commission of Texas Mentor/Protégé Program is developed in accordance with Government Code 2161.065 and
More information